EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
Academic Article
Overview
abstract
publication date
published in
Identity
Digital Object Identifier (DOI)
-
10.1080/14796694.2025.2567840
PubMed ID